Clinical trials
Atrophy clinical trials
Below are recruiting atrophy clinical trials, each written for real people, not researchers. We’re tracking 268 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06900374Recruiting
Radiofrequency treatment for vaginal dryness in breast cancer patients
This trial tests if a gentle radiofrequency treatment can help breast cancer patients with vaginal dryness that hasn't improved with standard moisturizers. It aims to improve comfort and quality of life.
LilleAges 40 years+ - NCT06888661Enrolling by invitationEarly Phase 1
Testing EXG001-307 for spinal muscular atrophy in infants
This trial tests a new medicine called EXG001-307 for babies with spinal muscular atrophy (SMA) types 1 and 2. The goal is to see if it is safe and helps with muscle strength and breathing.
Shanghai, Shanghai MunicipalityAges 1 day–2 years - NCT06868628RecruitingPhase 2
Nasal spray for multiple system atrophy (MSA) study
This trial tests a nasal spray called Foralumab for people with multiple system atrophy (MSA). The goal is to see if the spray can help reduce symptoms or slow the disease. It is for people who are otherwise healthy enough to safely participate.
Boston, MassachusettsAges 30–85 - NCT05824169RecruitingPhase 1/Phase 2
Gene therapy for babies with severe spinal muscular atrophy
This early-stage study tests whether a one-time gene therapy can safely improve outcomes for babies with the most severe type of spinal muscular atrophy (SMA type 1). It focuses on safety and early signs of benefit, and participation requires specific genetic and health criteria.
BeijingAges birth–6 months - NCT06421831RecruitingPhase 1/Phase 2
Gene therapy trial for spinal muscular atrophy type 3
This trial is testing a one-time gene therapy drug for people with SMA type 3. The goal is to see if it can safely improve muscle function and strength.
Beijing, Beijing MunicipalityAges 2 years+ - NCT06396325Recruiting
Active video game trial for arm strength in kids with SMA
This trial tests whether playing active video games (exergaming) with your arms can help children and teens with spinal muscular atrophy improve their arm strength and function. If you join, you'll play specially designed games for a period of time, and researchers will see if it makes a difference.
Calgary, AlbertaAges 8–18 - NCT06831500RecruitingPhase 1/Phase 2
Study on carbidopa/levodopa ratio for low blood pressure in MSA-P and Parkinson's
This study tests whether adjusting the ratio of carbidopa and levodopa (medications used for Parkinson's) can help reduce dizziness or fainting from low blood pressure when standing up, in people with Multiple System Atrophy (Parkinsonian type) or Parkinson's disease.
Lausanne, Canton of VaudAges Any age - NCT06821256Recruiting
Testing brain stimulation for multiple system atrophy
This trial tests if a gentle electrical current applied to the scalp can help people with a specific type of multiple system atrophy (the cerebellar variant) improve walking and other symptoms. The goal is to see if this non-invasive treatment is safe and effective.
Salerno, SaAges 40–90 - NCT04250493Recruiting
Testing insulin resistance in multiple system atrophy
This study looks at how the body handles blood sugar (insulin resistance) in people with multiple system atrophy (MSA). Results may help doctors understand the disease better and explore new ways to monitor or treat it.
BordeauxAges 30 years+ - NCT06772402Enrolling by invitation
Gene therapy for children with type 2 SMA
This trial tests a new gene therapy called GCB-001 for children with type 2 spinal muscular atrophy who can sit but not walk. It aims to improve muscle function and overall health.
Hangzhou, ZhejiangAges 2–12 - NCT06765980RecruitingPhase 1/Phase 2
Study of KRIYA-825 for geographic atrophy in age-related macular degeneration
This trial tests an experimental drug called KRIYA-825 (also known as VV-14295) for people with geographic atrophy, a late stage of dry age-related macular degeneration that causes vision loss. The study aims to see if the treatment is safe and can help slow the progression of the disease.
Erie, PennsylvaniaAges 55–80 - NCT06659549RecruitingPhase 2
Eye drop treatment for advanced dry AMD with geographic atrophy
This trial tests a daily eye drop (GAL-101) to see if it can slow the growth of geographic atrophy lesions in people with dry age-related macular degeneration (AMD) when the center of the macula is not yet involved.
Beverly Hills, CaliforniaAges 55 years+ - NCT06635148RecruitingPhase 2/Phase 3
Long-term study for geographic atrophy treatment
This study is for people who already took part in a previous trial for geographic atrophy (a late stage of dry age-related macular degeneration) and received the study drug or a sham. It looks at the long-term safety of the treatment over time.
Tucson, ArizonaAges 60 years+ - NCT06555419RecruitingPhase 1
Nusinersen dosing study via flexible spinal catheter
This trial investigates how the drug nusinersen (Spinraza) enters the body when given through a small, flexible tube placed in the lower back (ThecaFlex DRx system). It aims to learn how the drug is processed in adults and children with spinal muscular atrophy, which could help make dosing more convenient.
Phoenix, ArizonaAges 3 years+ - NCT06557460RecruitingPhase 2
Cell implant for advanced dry age-related macular degeneration
This trial tests a patch of retinal cells implanted under the retina to see if it can slow or stop vision loss from advanced dry AMD (geographic atrophy). It may help people whose central vision is already affected.
Huntington Beach, CaliforniaAges 55–90 - NCT06541704RecruitingPhase 3
Study of pozelimab with cemdisiran for geographic atrophy
This trial tests a combination of two study drugs (pozelimab and cemdisiran) given as a shot under the skin to slow the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes blind spots in central vision.
Chandler, ArizonaAges 50–85 - NCT06532474Recruiting
Muscle function study in SMA patients on SMN therapies
This study looks at how muscles work in children and young adults with spinal muscular atrophy (SMA) who are taking or starting SMN-directed therapies (like Evrysdi, Spinraza, or Zolgensma). It aims to understand the body's response to these treatments, which could help improve future care.
Memphis, TennesseeAges 5–20 - NCT06321965Recruiting
Study of SMA in Children on SMN-Boosting Therapies
This study is looking for children and teens with spinal muscular atrophy (SMA) who are already on a treatment like Spinraza, Evrysdi, or Zolgensma. The goal is to understand different forms of SMA and how the treatment affects them over time.
Bron, RhoneAges birth–16 years - NCT06197568RecruitingPhase 2
Study of AZU-101 cream for vaginal dryness in menopause
This study tests an experimental vaginal cream (AZU-101) for postmenopausal women who have vaginal dryness and pain during sex. The goal is to see if it can improve these symptoms without the risks of hormone treatments.
Saint Paul, MinnesotaAges 45–60 - NCT05953090Recruiting
Vaginal irritation study with device use and long follow-up
This trial studies a treatment for long-lasting vaginal/vulvar irritation caused by conditions like vaginal atrophy or certain skin conditions of the vulva. You would try the study product/device and be followed over time to see how symptoms recover.
Birmingham, AlabamaAges 18 years+ - NCT05861986RecruitingPhase 4
Risdiplam for very young children after gene therapy for SMA
This trial studies whether risdiplam, given early after gene therapy, is safe and helps children with spinal muscular atrophy (SMA) keep improving or stay stable. It focuses on children under 2 years old who already received gene therapy and need to meet timing and health requirements.
Little Rock, ArkansasAges 3 months–2 years - NCT05861999RecruitingPhase 4
Risdiplam for young children with SMA after gene therapy plateau
This trial studies whether risdiplam is safe and helpful for children under 2 with spinal muscular atrophy (SMA) whose function has leveled off or declined after gene therapy. It may be an option if you saw benefits from gene therapy but then noticed a stop or setback in key abilities.
Little Rock, ArkansasAges 3 months–2 years - NCT05866419Recruiting
Study of a port and catheter system for spinal muscular atrophy
This study tests a new device called the ThecaFlex DRx System, which is a small port and catheter placed under the skin to deliver Spinraza directly into spinal fluid—instead of needing repeated spinal taps. The device aims to make receiving medication easier and safer for people with SMA.
Phoenix, ArizonaAges 3 years+ - NCT05789758Recruiting
Study of Spinraza in pregnancy for 5q spinal muscular atrophy
This study looks at how Spinraza (nusinersen) taken during or before pregnancy affects people with 5q spinal muscular atrophy (SMA) and the health of their babies. It mainly fits those who were pregnant and received Spinraza around the time of conception or during pregnancy.
Palo Alto, CaliforniaAges 18–54
Hear when a new Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for atrophy?
- Yes. Clin2 currently lists 268 recruiting atrophy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a atrophy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a atrophy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.